Abstract: A method for controlling an exhaust gas treatment system is provided. The exhaust gas treatment system includes an exhaust gas stream supplied by an exhaust gas source to a selective catalytic reduction device, and a reductant supply source utilizing a volumetric pump. The exhaust gas source can include an internal combustion engine (ICE), such as a gasoline or diesel ICE. The method for controlling an exhaust gas treatment system includes commanding a reductant dosing quantity, determining a volumetric pump energizing time, determining an energizing time correction, and energizing the pump. The volumetric pump can comprise pump logic, and the volumetric pump energizing time can be determined by the pump logic. The energizing time correction can be determined using a calibration table. The calibration table can prescribe an energizing time correction based on a current pump pressure and the commanded dosing quantity.

Abstract: A method for controlling an exhaust gas treatment system is provided. The exhaust gas treatment system includes an exhaust gas stream supplied by an exhaust gas source to a selective catalytic reduction device, and a reductant supply source utilizing a volumetric pump. The exhaust gas source can include an internal combustion engine (ICE), such as a gasoline or diesel ICE. The method for controlling an exhaust gas treatment system includes commanding a reductant dosing quantity, determining a volumetric pump energizing time, determining an energizing time correction, and energizing the pump. The volumetric pump can comprise pump logic, and the volumetric pump energizing time can be determined by the pump logic. The energizing time correction can be determined using a calibration table. The calibration table can prescribe an energizing time correction based on a current pump pressure and the commanded dosing quantity.

Abstract: Methods and compositions are described for treating osteoarthritis. Treatment is described with a new class of anti-OA drug, namely compounds that may be used as lubricants of the tissue diagnosed with OA. Additionally, the present invention provides reagents for the screening of compounds that may be used as therapeutic agents in the treatment of OA.